Pfizer reported third-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of 87 cents versus the expected 73 cents, and revenue of $16.58 billion beating the $15.87 billion forecast. The company raised its full-year revenue guidance to $62 billion to $64 billion, up from $60.5 billion to $62.5 billion, and increased its adjusted profit forecast to $2.95 to $3.05 per share. These improvements reflect Pfizer's strong year-to-date performance and ongoing cost-cutting efforts. Additionally, Cecile Guegan, a long-time finance leader at Pfizer, has officially become the company's CFO after serving as interim CFO since August.
Pfizer shares are trading at USD 30.76 on Pluang as of Nov 03, 2026 19:02 WIB, showing a modest 0.29% increase in one day. The stock's dividend yield stands at 5.61%, reflecting steady income potential for investors. Pluang users currently favor buying Pfizer, with 63% of order activity leaning that way.
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
Pfizer's stock rating was lowered from Buy to Hold due to increasing analyst skepticism about its growth prospects and declining revenue and earnings expected through 2029. Despite management's optimistic projections and new pipeline drugs, including...
